Are there additional fees?
No — the price includes analysis, interpretation, and reporting.
Pricing
Overview
LiquidMammo™ is currently under validation as a CLIA Laboratory Developed Test (LDT). Pricing reflects early‑access development phases and may be adjusted as performance data and payer coverage evolve.
LiquidMammo is not yet FDA‑cleared or FDA‑approved. Pricing details below apply only during validation.
Self‑pay pricing
$395
Includes molecular analysis of circulating microRNAs, test classification, and clinician‑ready reporting with density‑aware interpretation.
Payment is typically processed through participating clinics. Some providers may offer installment or financing options.
Insurance & coverage
Coverage for Laboratory Developed Tests (LDTs) may vary by payer. As validation progresses, we will work with clinics and insurers on coverage pathways.
- Patients may use HSA/FSA depending on clinic policy.
- Coverage depends on payer policies and clinical indications.
- Clinics may offer bundled screening packages that include LiquidMammo.
Clinic & partner pricing
Volume pricing and partnership rates are available for multi‑clinic groups, health systems, and research collaborators.
- Discounted pricing for large screening volumes.
- Reduced pricing for validation participation.
- Bundled pricing for integrated clinical workflows.
Frequently asked
Do clinics bill patients?
Typically yes. Clinics handle billing directly during early‑access.
Are refunds available?
Refunds follow the policies of the clinic performing the blood draw.